人巨细胞病毒
免疫学
细胞疗法
过继性细胞移植
嵌合抗原受体
免疫系统
生物
先天免疫系统
医学
疾病
T细胞
表位
细胞
癌症研究
白细胞介素21
CD8型
病毒学
NK-92
病毒
受体
T细胞受体
淋巴因子激活杀伤细胞
细胞毒性
免疫疗法
Janus激酶3
自然杀伤细胞
抗原
遗传增强
移植排斥反应
主要组织相容性复合体
人类白细胞抗原
作者
Frederik Fabian Feigl,Ivo Schirmeister,Kristina Roth,Anne Halenius,Elvira D’Ippolito,Stephan Fricke,Ronny Baber,Isabella Metelmann,Sebastian Krämer,Ulrike Koehl,Dominik Schmiedel
出处
期刊:
[Elsevier BV]
日期:2026-10-01
卷期号:: 100105-100105
标识
DOI:10.1016/j.bict.2026.100105
摘要
Human cytomegalovirus (HCMV) is a widespread pathogen which establishes lifelong infection with latently infected cells and remains a major threat to immunocompromised individuals, including transplant recipients or patients receiving immunosuppressive therapy. Standard antiviral agents are not universally effective and are often unsuitable for prolonged use, underscoring the need for additional therapeutic strategies. Adoptive transfer of HCMV-specific T cells has demonstrated clinical efficacy; but its application is limited by donor compatibility, high costs, and restricted availability. Natural killer (NK) cells, conversely, combine potent intrinsic antiviral activity with a favorable safety profile, rendering them an attractive alternative platform for genetic engineering. In this study, we describe the first single-step generation of peripheral blood NK cells engineered to express a T cell receptor (TCR) that recognizes the HLA-A*02:01–restricted HCMV pp65 epitope NLVPMVATV. These TCR-NK cells demonstrated stable expression of the introduced TCR while retaining NK cell receptor repertoires. Functional analysis revealed both innate NK cell-mediated cytotoxicity and robust antigen-specific activity through the introduced TCR. Notably, these engineered TCR-NK cells were able to recognize and lyse HCMV TB40-infected fibroblasts as well as single-cell suspensions of primary human lung tissue infected with the same strain, demonstrating efficacy in physiologically relevant contexts. Our findings provide the first demonstration of TCR-engineered NK cells targeting an infectious disease and establish a proof-of-concept for their clinical development. The ability to generate allogeneic cells in a streamlined, enrichment-free process highlights their potential as an “off-the-shelf” advanced therapy medicinal product (ATMP) for patients where conventional antiviral therapy is insufficient.
科研通智能强力驱动
Strongly Powered by AbleSci AI